The newest case is the fifth to bring similar allegations against Moderna in the same court, with three others, all filed Nov ...

Our primary commercial efforts remain dedicated to the largest ... give this vaccine candidate the highest probability of ...

The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

The holidays are fast approaching along with cooler weather and various respiratory illnesses. Here's when to get your ...

A Trinity Life Sciences report found that more pharma product launches were successful in 2023 than the year before. Here are ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates Achieved total ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Moderna (MRNA) announced Health Canada has approved mRESVIA for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults 60 years of ...

Bank of America Securities analyst Alec Stranahan reiterated a Hold rating on Moderna (MRNA – Research Report) today and set a price ...

The Cambridge-based company’s latest COVID shot was approved three weeks earlier than last year, according to a statement ...

Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...